L1-79 is an investigational new drug that targets the core deficits in social-interaction in ASD. 

L1-79 has been administered to over 80 individuals and has been well tolerated to-date.

If you are interested in learning more about participating in upcoming studies of L1-79, please submit the requested information at the following link:

https://www.yamopharma.com/participation-in-future-clinical-studies/